Cognition Therapeutics (CGTX) Liabilities and Shareholders Equity (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $36.1 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 53.79% year-over-year to $36.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147.5 million (up 27.55% YoY) and the FY2025 annual result came in at $48.4 million, up 60.05% from the prior year.
• Liabilities and Shareholders Equity fell to $36.1 million in Q1 2026 per CGTX's latest filing, from $48.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $58.7 million in Q1 2022 and bottomed at $19.6 million in Q2 2025.
• The 5-year median for Liabilities and Shareholders Equity is $38.9 million (2024), against an average of $40.1 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity soared 300.01%; it then slumped 42.91% in 2025.
• Tracing CGTX's Liabilities and Shareholders Equity over 5 years: stood at $50.4 million in 2022, then tumbled by 30.27% to $35.2 million in 2023, then dropped by 14.02% to $30.2 million in 2024, then jumped by 60.05% to $48.4 million in 2025, then dropped by 25.32% to $36.1 million in 2026.
• Per Business Quant, the three latest CGTX Liabilities and Shareholders Equity figures stand at $36.1 million (Q1 2026), $48.4 million (Q4 2025), and $43.4 million (Q3 2025).

Peer Comparison